Pamela Wang, MD
Internal Medicine · Danville, CANPI 1033188602
Payments from drug & device makers
Across 206 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$642
- AbbVie$433
- Currax Pharmaceuticals LLC$340
- Novo Nordisk$315
- Lilly USA, LLC$286
- Eisai Inc.$239
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,95699%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 33 | $642 |
| AbbVie(2 entities) | 23 | $433 |
| Currax Pharmaceuticals LLC | 35 | $340 |
| Novo Nordisk | 16 | $315 |
| Lilly USA, LLC | 11 | $286 |
| Eisai Inc. | 3 | $239 |
| Pfizer | 7 | $195 |
| Therapeuticsmd, Inc. | 10 | $177 |
| Novartis | 6 | $136 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $110 |
| GSK | 5 | $97 |
| Boehringer Ingelheim | 5 | $89 |
| Astellas Pharma US Inc | 4 | $88 |
| Aimmune Therapeutics, Inc. | 3 | $80 |
| Nestle Healthcare Nutrition Inc. | 3 | $75 |
| Exact Sciences | 3 | $74 |
| Kowa Pharmaceuticals America, Inc. | 3 | $66 |
| Esperion Therapeutics, Inc. | 2 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Phathom Pharmaceuticals, Inc. | 2 | $42 |
| Mayne Pharma Commercial LLC | 4 | $42 |
| Biohaven Pharmaceuticals, Inc. | 2 | $41 |
| Bausch Health US, LLC | 2 | $38 |
| Endo Pharmaceuticals Inc. | 2 | $35 |
| Alfasigma USA, Inc. | 1 | $34 |
| AstraZeneca | 1 | $29 |
| Corium, LLC | 1 | $25 |
| Ascend Therapeutics US, LLC | 2 | $25 |
| Acella Pharmaceuticals, LLC | 1 | $24 |
| IBSA Pharma Inc. | 1 | $22 |
| Merck | 1 | $17 |
| Avion Pharmaceuticals | 1 | $16 |
| Biogen | 1 | $16 |
| Lupin Inc. | 1 | $16 |
| Exeltis, USA Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Leqembi$222
How this compares
$4,006 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 72 | $68,765 |
| OzempicSemaglutide | 66 | $61,900 |
| MounjaroTirzepatide | 53 | $58,551 |
| TrulicityDulaglutide | 40 | $39,081 |
| JardianceEmpagliflozin | 15 | $24,304 |
| EliquisApixaban | 16 | $15,391 |
| SynthroidLevothyroxine Sodium | 56 | $6,075 |
| Estradiol | 55 | $4,972 |
| Dexlansoprazole DrDexlansoprazole | 12 | $4,857 |
| Rosuvastatin Calcium | 246 | $4,812 |
| Levothyroxine Sodium | 181 | $3,768 |
| YuvafemEstradiol | 20 | $3,031 |
| ImvexxyEstradiol | 13 | $2,735 |
| Armour ThyroidThyroid,pork | 22 | $2,630 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,434 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $286 | $97,63293 claims |
| Novo NordiskOzempic | $315 | $61,90066 claims |
| Boehringer IngelheimJardiance | $89 | $24,30415 claims |
| PfizerEliquis, Paxlovid | $195 | $16,82044 claims |
| AbbVieSynthroid, Armour Thyroid | $433 | $8,70578 claims |
| Therapeuticsmd, Inc.Imvexxy | $177 | $2,73513 claims |
| GSKArnuity Ellipta | $97 | $2,43412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Danville
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.